adx-038
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2023 (NCT05876312)
Timeline
Indications
Mechanism of action
- Complement C5ANTISENSE INHIBITOR
C5 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06990269 | Phase 2 | Nov 30, 2025 | ADARx Pharmaceuticals, Inc. |
| NCT06989359 | Phase 2 | Jul 31, 2025 | ADARx Pharmaceuticals, Inc. |
| NCT05876312 | Phase 1 | Jul 3, 2023 | ADARx Pharmaceuticals, Inc., Novotech |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. | For profit | 3 | 3 | 2 | 2023 |
| Novotech | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1